<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179815</url>
  </required_header>
  <id_info>
    <org_study_id>EKSG 01/114/L</org_study_id>
    <secondary_id>EKSG 01/114/3B</secondary_id>
    <secondary_id>KEK 025/10</secondary_id>
    <nct_id>NCT01179815</nct_id>
  </id_info>
  <brief_title>Swiss Diabetes Registry - SwissDiab Study</brief_title>
  <acronym>SwissDiab</acronym>
  <official_title>Swiss Diabetes Registry - SwissDiab Study, a Prospective Cohort Study of Patients With Diabetes in Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the estimated number of people with diabetes mellitus is approximately 387 million&#xD;
      people worldwide. Due to population growth, urbanization, ageing and the rising prevalence of&#xD;
      obesity the numbers of individuals with diabetes is increasing likewise. It has been shown&#xD;
      that improving glycemic control is associated with a reduction in late complications of&#xD;
      diabetes, such as cardiovascular and microvascular diseases. Therefore, treatment guidelines&#xD;
      were established internationally by large and renowned associations and adopted by many&#xD;
      countries.&#xD;
&#xD;
      For Switzerland only sparse data exist on the actual implementation of such recommendations&#xD;
      and on patient's well-being. The Swiss Diabetes Registry - SwissDiab Study is a prospective&#xD;
      cohort study aiming at including and collecting data of virtually all patients regularly seen&#xD;
      and treated at the study centers (≈ 500 patients each), irrespective of type, duration of&#xD;
      diabetes or treatment . This allows the evaluation of diabetes treatment strategies at these&#xD;
      centers. Furthermore, risk indicators for micro- and macrovascular complications, mortality&#xD;
      as well as costs and quality of life will be assessed. Data will be recorded through an&#xD;
      internet-based, electronic database specifically designed for this study. At a later&#xD;
      perspective it is planned to extend data collection to general practitioner/family doctor&#xD;
      networks in order to include a larger and more representative sample of patients with&#xD;
      diabetes in Switzerland.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Currently, approximately 387 million people worldwide are affected by Diabetes Mellitus.&#xD;
&#xD;
      Due to population growth, urbanization, ageing and the rising prevalence of obesity the&#xD;
      numbers of individuals with diabetes will grow. The American Diabetes Association estimated&#xD;
      the total cost of diabetes in the US in 2012 at $245 billion. The greatest share of those&#xD;
      costs results from the treatment of diabetes-associated complications caused by prolonged&#xD;
      hyperglycemia. There is compelling evidence that tight glycemic control and intensive&#xD;
      treatment of other cardiovascular risk factors substantially reduce the risk of developing&#xD;
      being also cost-effective. Our current knowledge, however, is mainly derived from&#xD;
      intervention trials usually including strictly defined patient groups and are carried out&#xD;
      according to meticulous study protocols. Observational studies, however, in unselected&#xD;
      outpatient settings have revealed discrepancies between recommended treatment goals resulting&#xD;
      from those latter studies and actual standard of care. There is a pressing need, therefore,&#xD;
      to assess the standard of care and confirm the feasibility and effectiveness of proposed&#xD;
      management trends in both specialty clinic and community-based cohorts.&#xD;
&#xD;
      Objective&#xD;
&#xD;
        1. With the help of an internet-based, electronic database (webspirit®, www.swissdiab.ch):&#xD;
           to collect representative cross-sectional data from all consenting patients seen and&#xD;
           treated at the study centers in order to evaluate the current standard of care of&#xD;
           patients with diabetes mellitus, the distribution of micro- and macrovascular&#xD;
           complications, the use of medications and devices as well as aspects of costs and&#xD;
           quality of life (QoL)&#xD;
&#xD;
        2. To collect prospective data of those patients in relation to achievement of treatment&#xD;
           goals, changes in management, risk factors for, incidence and progression of micro- and&#xD;
           macrovascular complications, mortality as well as costs and quality of life using the&#xD;
           same database&#xD;
&#xD;
      Methods&#xD;
&#xD;
      After obtaining informed consent, patients with diabetes mellitus willing to participate will&#xD;
      be invited to an initial comprehensive assessment (baseline) performed at the three cantonal&#xD;
      study centers (Inselspital Bern, Kantonsspital St. Gallen, Universitätsspital Zürich). This&#xD;
      will be followed by face-to-face clinical/laboratory visits between one to four times yearly&#xD;
      according to patient's individual management plans. Once a year a comprehensive review&#xD;
      including clinical and laboratory screening for diabetes-specific complications is planned.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2099</completion_date>
  <primary_completion_date type="Anticipated">January 2099</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>annually</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macrovascular morbidity</measure>
    <time_frame>annually</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular morbidity</measure>
    <time_frame>annually</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>annually</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and full blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with diabetes above age 18 are eligible for this study, irrespective of type,&#xD;
        duration of diabetes or treatment. Diabetes will be defined according to the current&#xD;
        diagnosis criteria suggested by the American Diabetes Association (fasting plasma glucose ≥&#xD;
        7mmol/L, occasional plasma glucose ≥11.1mmol/L (plus typical symptoms), a 2hour plasma&#xD;
        glucose of ≥11.1mmol/L after a 75g oral glucose tolerance test, or a HbA1c ≥ 6.5%), but&#xD;
        patients under treatment with ≥2 oral hypoglycemic agents (OHA) and/or insulin in the&#xD;
        absence of proof of a diagnosis by fasting, random plasma glucose or oral glucose tolerance&#xD;
        test will also be included. The type of diabetes will be diagnosed clinically in most&#xD;
        cases. In equivocal cases classification will be based on previously reported criteria with&#xD;
        the assistance of laboratory test results.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus according to ADA criteria&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with gestational diabetes mellitus, patients unable to give informed consent,&#xD;
             legally incompetent or incapable to comply with the study terms and conditions as well&#xD;
             as patients with significantly reduced life expectancy (&lt;1 year) will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Brändle, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. of Endocrinology, Diabetes and Clinical Nutrition, Kantonsspital St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Laimer, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger Lehmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Div. of Endocrinology, Diabetes and Clin. Nutrition, University Hospital Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Laimer, PD Dr. med.</last_name>
    <phone>+41 31 632 30 62</phone>
    <email>Markus.Laimer@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Stettler, Prof.</last_name>
    <phone>+41 31 632 40 70</phone>
    <email>christoph.stettler@insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätspoliklinik für Endokrinologie, Diabetologie und Klinische Ernährung, Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Laimer, PD Dr. med.</last_name>
      <phone>+41 31 632 30 62</phone>
      <email>Markus.Laimer@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Stettler, Prof.</last_name>
      <phone>+41 31 632 40 70</phone>
      <email>christoph.stettler@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Markus Laimer, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Diem, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katja Müller-Fischer, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'endocrinologie, diabétologie et métabolisme</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Schwitzgebel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Endokrinologie, Diabetologie, Osteologie und Stoffwechselerkrankungen, Kantonsspital St.Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Brändle, Prof. Dr. med., M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrin Schimke, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roger Lehmann, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Krützfeld, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giatgen Spinas, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Gerber, PD Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients with type 1 or type 2 diabetes mellitus</keyword>
  <keyword>Monogenetic diabetes</keyword>
  <keyword>Pancreatogenic diabetes,</keyword>
  <keyword>Drug-induced diabetes, other forms</keyword>
  <keyword>Cohort Studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

